The Challenges of Eradicating Pediatric Helicobacter pylori Infection in the Era of Probiotics
暂无分享,去创建一个
[1] C. Mărginean,et al. The Yin-Yang Concept of Pediatric Obesity and Gut Microbiota , 2022, Biomedicines.
[2] C. Bănescu,et al. Innate Immune Responses in Pediatric Patients with Gastritis—A Trademark of Infection or Chronic Inflammation? , 2022, Children.
[3] Alina Boglis,et al. Innate immunity – the hallmark of Helicobacter pylori infection in pediatric chronic gastritis , 2021, World journal of clinical cases.
[4] C. Mărginean,et al. Gastric Microenvironment—A Partnership between Innate Immunity and Gastric Microbiota Tricks Helicobacter pylori , 2021, Journal of clinical medicine.
[5] R. Nasr,et al. The Crosstalk between Microbiome and Immune Response in Gastric Cancer , 2020, International journal of molecular sciences.
[6] L. Kupčinskas,et al. Transient and Persistent Gastric Microbiome: Adherence of Bacteria in Gastric Cancer and Dyspeptic Patient Biopsies after Washing , 2020, Journal of clinical medicine.
[7] Peng-Chieh Chen,et al. Probiotics-Containing Yogurt Ingestion and H. pylori Eradication Can Restore Fecal Faecalibacterium prausnitzii Dysbiosis in H. pylori-Infected Children , 2020, Biomedicines.
[8] J. Gisbert,et al. Systematic review: gastric microbiota in health and disease , 2020, Alimentary pharmacology & therapeutics.
[9] Alina Boglis,et al. The relationship between TLR4 rs4986790 and rs4986791 gene polymorphisms and Helicobacter pylori infection in children with gastritis. , 2019, Pathology, research and practice.
[10] A. Falanga,et al. Beta-defensins and analogs in Helicobacter pylori infections: mRNA expression levels, DNA methylation, and antibacterial activity , 2019, PloS one.
[11] S. Laneri,et al. A Novel View of Human Helicobacter pylori Infections: Interplay between Microbiota and Beta-Defensins , 2019, Biomolecules.
[12] C. Mărginean,et al. The Relationship between Toll-like Receptors and Helicobacter pylori-Related Gastropathies: Still a Controversial Topic , 2019, Journal of immunology research.
[13] Y. Xiong,et al. Analysis of culturable microbiota present in the stomach of children with gastric symptoms , 2018, Brazilian Journal of Microbiology.
[14] H. Yonezawa,et al. Role of Probiotics in Eradication Therapy for Helicobacter pylori Infection. , 2019, Advances in experimental medicine and biology.
[15] J. G. Kusters,et al. Future of Helicobacter pylori and its feasibility , 2018, Expert review of anti-infective therapy.
[16] B. Johnston,et al. Probiotics to Prevent Clostridium difficile Infection in Patients Receiving Antibiotics. , 2018, JAMA.
[17] D. Bravo,et al. Helicobacter pylori in human health and disease: Mechanisms for local gastric and systemic effects. , 2018, World journal of gastroenterology.
[18] M. Barone,et al. Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis , 2018, World journal of gastroenterology.
[19] J. L. Costa,et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota , 2017, Gut.
[20] T. Alarcón,et al. Helicobacter pylori treatment: antibiotics or probiotics , 2017, Applied Microbiology and Biotechnology.
[21] Jianhua He,et al. Probiotics in 14-day triple therapy for Asian pediatric patients with Helicobacter pylori infection: a network meta-analysis , 2017, Oncotarget.
[22] Jing Liu,et al. Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. , 2017, Clinics and research in hepatology and gastroenterology.
[23] F. Bäckhed,et al. Evolution, human-microbe interactions, and life history plasticity , 2017, The Lancet.
[24] Jing Liu,et al. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis , 2017, European Journal of Clinical Pharmacology.
[25] A. Evans,et al. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. , 2017, Gastroenterology.
[26] Banu N Şirvan,et al. Are Synbiotics added to the Standard Therapy to eradicate Helicobacter pylori in Children Beneficial? A Randomized Controlled Study , 2017, Euroasian journal of hepato-gastroenterology.
[27] N. Lu,et al. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance , 2017, Frontiers in cellular and infection microbiology.
[28] Linda M Krisch,et al. From inflammation to gastric cancer – the importance of Hedgehog/GLI signaling in Helicobacter pylori-induced chronic inflammatory and neoplastic diseases , 2017, Cell Communication and Signaling.
[29] Zhan Gao,et al. Characterization of the Gastric Microbiota in a Pediatric Population According to Helicobacter pylori Status , 2017, The Pediatric infectious disease journal.
[30] E. Lefkowitz,et al. Helicobacter pylori Infection is Associated with an Altered Gastric Microbiota in Children , 2016, Mucosal Immunology.
[31] R. Peek,et al. DNA Transfer and Toll-like Receptor Modulation by Helicobacter pylori. , 2017, Current topics in microbiology and immunology.
[32] Antonio Gasbarrini,et al. Antibiotics as deep modulators of gut microbiota: between good and evil , 2016, Gut.
[33] P. Malfertheiner,et al. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events , 2016, United European gastroenterology journal.
[34] Bong-Soo Kim,et al. The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial , 2016, Helicobacter.
[35] H. Adanir,et al. Local Immune Response in Helicobacter pylori Infection , 2016, Medicine.
[36] Li Yang,et al. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review , 2016, American journal of therapeutics.
[37] T. Sugiyama,et al. Novel epidermal growth factor receptor pathway mediates release of human β-defensin 3 from Helicobacter pylori-infected gastric epithelial cells. , 2016, Pathogens and disease.
[38] Chao Lu,et al. Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis , 2016, Scientific Reports.
[39] M. Emara,et al. Emerging Role of Probiotics in the Management of Helicobacter Pylori Infection: Histopathologic Perspectives , 2016, Helicobacter.
[40] J. Ball,et al. An ancestral host defence peptide within human β-defensin 3 recapitulates the antibacterial and antiviral activity of the full-length molecule , 2015, Scientific Reports.
[41] T. Pieber,et al. Effects of high doses of vitamin D3 on mucosa-associated gut microbiome vary between regions of the human gastrointestinal tract , 2015, European Journal of Nutrition.
[42] H. Szajewska,et al. Systematic review with meta‐analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection , 2015, Alimentary pharmacology & therapeutics.
[43] Wei Qian,et al. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. , 2015, World journal of gastroenterology.
[44] J. Gisbert,et al. Helicobacter pylori second‐line rescue therapy with levofloxacin‐ and bismuth‐containing quadruple therapy, after failure of standard triple or non‐bismuth quadruple treatments , 2015, Alimentary pharmacology & therapeutics.
[45] Jeffrey L. Curtis,et al. Analysis of the Upper Respiratory Tract Microbiotas as the Source of the Lung and Gastric Microbiotas in Healthy Individuals , 2015, mBio.
[46] A. Sharara,et al. Efficacy of reduced-dose regimen of a capsule containing bismuth subcitrate, metronidazole, and tetracycline given with amoxicillin and esomeprazole in the treatment of Helicobacter Pylori infection , 2015, United European gastroenterology journal.
[47] Nayoung Kim,et al. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection , 2014, Gut and liver.
[48] T. Deng,et al. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. , 2015, Internal medicine.
[49] V. Papastergiou,et al. Treatment of Helicobacter pylori infection: Past, present and future. , 2014, World journal of gastrointestinal pathophysiology.
[50] P. Ruggiero. Use of probiotics in the fight against Helicobacter pylori. , 2014, World journal of gastrointestinal pathophysiology.
[51] Guoxin Zhang,et al. The Effect of Probiotics Supplementation on Helicobacter pylori Eradication Rates and Side Effects during Eradication Therapy: A Meta-Analysis , 2014, PloS one.
[52] Hongyu Zhang,et al. Helicobacter pylori Dwelling on the Apical Surface of Gastrointestinal Epithelium Damages the Mucosal Barrier Through Direct Contact , 2014, Helicobacter.
[53] Keng-Liang Wu,et al. Levofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice , 2014, Biomedical journal.
[54] F. Hanisch,et al. Human Trefoil Factor 2 Is a Lectin That Binds α-GlcNAc-capped Mucin Glycans with Antibiotic Activity against Helicobacter pylori* , 2014, The Journal of Biological Chemistry.
[55] V. Papastergiou,et al. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. , 2014, World journal of gastroenterology.
[56] Glenn R. Gibson,et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic , 2014 .
[57] Z. Tian,et al. Participation of microbiota in the development of gastric cancer. , 2014, World journal of gastroenterology.
[58] S. Fagarasan,et al. Gut TFH and IgA: key players for regulation of bacterial communities and immune homeostasis , 2014, Immunology and cell biology.
[59] M. Emara,et al. Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial , 2014, Therapeutic advances in gastroenterology.
[60] J. Versalovic,et al. Lactobacillus reuteri Strain Combination In Helicobacter pylori Infection: A Randomized, Double-Blind, Placebo-Controlled Study , 2013, Journal of clinical gastroenterology.
[61] S. Backert,et al. Helicobacter pylori downregulates expression of human β-defensin 1 in the gastric mucosa in a type IV secretion-dependent fashion , 2013, Cellular microbiology.
[62] S. K. Ogata,et al. High Helicobacter pylori Resistance to Metronidazole and Clarithromycin in Brazilian Children and Adolescents , 2013, Journal of pediatric gastroenterology and nutrition.
[63] R. Mattar,et al. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study , 2013, BMC Gastroenterology.
[64] Mathilda Lindberg,et al. Helicobacter pylori and the gastric microbiota. , 2013, Best practice & research. Clinical gastroenterology.
[65] A. Seck,et al. Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients , 2013, Annals of Clinical Microbiology and Antimicrobials.
[66] H. Goossens,et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption , 2012, Gut.
[67] F. Fabbian,et al. Helicobacter pylori Infection in Clinical Practice: Probiotics and a Combination of Probiotics + Lactoferrin Improve Compliance, But Not Eradication, in Sequential Therapy , 2012, Helicobacter.
[68] B. Sheu,et al. Probiotics‐Containing Yogurts Suppress Helicobacter pylori Load and Modify Immune Response and Intestinal Microbiota in the Helicobacter pylori‐Infected Children , 2012, Helicobacter.
[69] M. Wiese,et al. Immunomodulatory effects of Lactobacillous plantarum and Helicobacter pylori CagA⁺ on the expression of selected superficial molecules on monocyte and lymphocyte and the synthesis of cytokines in whole blood culture. , 2012, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[70] C. Hassan,et al. Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics: a placebo-controlled pilot study. , 2012, Inflammation & allergy drug targets.
[71] J. Gisbert,et al. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori , 2012, Clinical and experimental gastroenterology.
[72] S. Kamiya. Effect of Probiotics on Intestinal Infections , 2011 .
[73] T. Wang,et al. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. , 2011, Gastroenterology.
[74] Y. Takei,et al. Risk for local recurrence of early gastric cancer treated with piecemeal endoscopic mucosal resection during a 10-year follow-up period , 2011, Surgical Endoscopy.
[75] C. Hassan,et al. Worldwide H. pylori antibiotic resistance: a systematic review. , 2010, Journal of gastrointestinal and liver diseases : JGLD.
[76] H. Szajewska,et al. Meta‐analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment , 2010, Alimentary pharmacology & therapeutics.
[77] T. Alarcón,et al. Detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies of pediatric patients by using a commercially available real-time polymerase chain reaction after NucliSens semiautomated DNA extraction. , 2010, Diagnostic microbiology and infectious disease.
[78] Vincent Wai-Sun Wong,et al. Bacterial Microbiota Profiling in Gastritis without Helicobacter pylori Infection or Non-Steroidal Anti-Inflammatory Drug Use , 2009, PloS one.
[79] A. Zullo,et al. Minimal inhibitory concentration (MIC) values and different point mutations in the 23S rRNA gene for clarithromycin resistance in Helicobacter pylori. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[80] Y. Koga,et al. Long‐term Administration of Probiotics to Asymptomatic Pre‐school Children for Either the Eradication or the Prevention of Helicobacter pylori Infection , 2009, Helicobacter.
[81] M. Jarosz,et al. Dietary and socio-economic factors in relation to Helicobacter pylori re-infection. , 2009, World journal of gastroenterology.
[82] S. Brand,et al. Expression of beta‐defensin 4 is increased in human gastritis , 2009, European journal of clinical investigation.
[83] H. Jung,et al. The Effects of Probiotics on PPI‐Triple Therapy for Helicobacter pylori Eradication , 2008, Helicobacter.
[84] K. Fellermann,et al. Probiotic lactobacilli and VSL#3 induce enterocyte β‐defensin 2 , 2008, Clinical and experimental immunology.
[85] A. Dursun,et al. Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylori Therapy: A Prospective Randomized Placebo‐Controlled Double‐Blind Study , 2007, Helicobacter.
[86] T. Iino,et al. Effect of Bifidobacterium bifidum fermented milk on Helicobacter pylori and serum pepsinogen levels in humans. , 2007, Journal of dairy science.
[87] T Rokkas,et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report , 2006, Gut.
[88] F. Mégraud,et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe , 2006, Gut.
[89] P. Dhar,et al. High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait , 2006, Alimentary pharmacology & therapeutics.
[90] E. Ierardi,et al. Lactobacillus reuteri therapy to reduce side‐effects during anti‐Helicobacter pylori treatment in children: a randomized placebo controlled trial , 2006, Alimentary pharmacology & therapeutics.
[91] M. Valencia,et al. Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children. , 2006, Nutrition.
[92] S. Koletzko,et al. Primary clarithromycin resistance to Helicobacter pylori and therapy failure in children: the experience in West Virginia. , 2006, Journal of pediatric gastroenterology and nutrition.
[93] N. Tsuji,et al. Human beta-defensin-3 induction in H. pylori-infected gastric mucosal tissues. , 2006, World journal of gastroenterology.
[94] J. Amlerová,et al. Effects of a Specially Designed Fermented Milk Product Containing Probiotic Lactobacillus casei DN-114 001 and the Eradication of H. pylori in Children: A Prospective Randomized Double-Blind Study , 2005, Journal of clinical gastroenterology.
[95] M. Balsitis,et al. Gastric epithelial anti-microbial peptides--histological correlation and influence of anatomical site and peptic ulcer disease. , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[96] Deng-Chyang Wu,et al. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. , 2004, The American journal of clinical nutrition.
[97] R. Hunt,et al. Helicobacter pylori Public Health Implications , 2004, Helicobacter.
[98] F. Russo,et al. The Influence of Lactobacillus brevis on Ornithine Decarboxylase Activity and Polyamine Profiles in Helicobacter pylori‐Infected Gastric Mucosa , 2004, Helicobacter.
[99] Farahnaz Nariman,et al. Susceptibilities to Different Antibiotics of Helicobacter pylori Strains Isolated from Patients at the Pediatric Medical Center of Tehran, Iran , 2004, Journal of Clinical Microbiology.
[100] E. Fontham,et al. Impact of Helicobacter pylori Infection on Growth of Children: A Prospective Cohort Study , 2003, Journal of pediatric gastroenterology and nutrition.
[101] M. Gotteland,et al. Suppressive effect of frequent ingestion of Lactobacillus johnsonii La1 on Helicobacter pylori colonization in asymptomatic volunteers. , 2003, The Journal of antimicrobial chemotherapy.
[102] Y. Pyun,et al. Antagonism of Helicobacter pylori by bacteriocins of lactic acid bacteria. , 2003, Journal of food protection.
[103] L. Piddock,et al. The importance of efflux pumps in bacterial antibiotic resistance. , 2003, The Journal of antimicrobial chemotherapy.
[104] A. Quinn,et al. Modulation of host antimicrobial peptide (β-defensins 1 and 2) expression during gastritis , 2001 .
[105] C. O'Morain,et al. Helicobacter pylori Infection , 1994 .
[106] T. Hirayama,et al. Expression of human beta-defensin 2 (hBD-2) in Helicobacter pylori induced gastritis: antibacterial effect of hBD-2 against Helicobacter pylori. , 2001, Gut.
[107] M. Konno,et al. Iron-deficiency anemia associated with Helicobacter pylori gastritis. , 2000, Journal of pediatric gastroenterology and nutrition.
[108] B. Trask,et al. Cloning and characterization of two Toll/Interleukin-1 receptor-like genes TIL3 and TIL4: evidence for a multi-gene receptor family in humans. , 1998, Blood.
[109] E. Kuipers,et al. Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer , 1997, Alimentary pharmacology & therapeutics.
[110] M. Blaser,et al. Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. , 1995, Cancer research.
[111] B. Marshall,et al. UNIDENTIFIED CURVED BACILLI IN THE STOMACH OF PATIENTS WITH GASTRITIS AND PEPTIC ULCERATION , 1984, The Lancet.
[112] J. Higginson,et al. International Agency for Research on Cancer. , 1968, WHO chronicle.